InMed Pharmaceuticals has amended its all-stock merger agreement with Mentari Therapeutics, a biotech company focused on migraine prevention. The amendment clarifies transaction sequencing, financing impact, and tax treatment. InMed also filed a Form S-4 registration statement with the SEC, outlining the merger's strategic rationale and next steps. The merger, approved by both companies' boards, is expected to close in Q4 2026 pending shareholder approval and regulatory conditions.
STARLUX Airlines has introduced the AIRSORAYAMA Silver, the world's largest flying canvas, featuring a unique liquid-metal livery designed by Japanese artist Hajime Sorayama. The aircraft, an Airbus A350-1000, was unveiled in Toulouse and will be pil...
Intertape Polymer Corp (IPG) has introduced a new PCR Air Pillow Film made with 50% recycled materials, including 35% post-consumer recycled content. This high-performance packaging film is designed to help companies meet sustainability goals without...
Spring Valley Acquisition Corp. III shareholders have approved a business combination with General Fusion, a leader in fusion energy technology. The merger will create the first publicly traded pure-play fusion company, expected to trade on Nasdaq un...
Ademi LLP is investigating Crinetics' recent $10 billion sale to Vertex for potential breaches of fiduciary duty by Crinetics' board and unfair deal terms. The deal offers Crinetics shareholders $85 per share but includes penalties that limit competi...
Bitcoin's Miner Cycle Stress Composite has dropped to a historically rare low in 2026, signaling miner stress levels similar to those seen near major market bottoms in 2015, 2018, and 2020. Around 20% of miners are currently operating at a loss due t...
